HistoSonics, Backed by Bezos Expeditions, Achieves $2.25B Valuation in Management-Led Deal

Minneapolis, August 7, 2025 (Business Wire) -- HistoSonics, developer of the Edison® Histotripsy System, has completed a management-led majority stake acquisition with a consortium of private and public investors, including K5 Global, Bezos Expeditions, and Wellington Management, valuing the company at approximately $2.25 billion. The investment positions HistoSonics to accelerate the growth of its Edison System across new clinical indications and global markets, while CEO Mike Blue will also assume the role of Chairman of the Board. The company plans to expand its histotripsy therapy beyond liver tumors to kidney, pancreas, and prostate applications, with a long-term goal of treating a broad range of benign and malignant conditions worldwide.

Read full article here.